Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

Rafael Carretero, Ena Wang, Ana I. Rodriguez, Jennifer Reinboth, Maria L. Ascierto, Alyson M. Engle, Hui Liu, Francisco M. Camacho, Francesco M. Marincola, Federico Garrido, Teresa Cabrera

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

We present the results of a comparative gene expression analysis of 15 metastases (10 regressing and 5 progressing) obtained from 2 melanoma patients with mixed response following different forms of immunotherapy. Whole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients. In contrast, progressing metastases showed low transcription levels of genes involved in these pathways. Histological analysis showed T cells and HLA-DR positive infiltrating cells in the regressing but not in the progressing metastases. Quantitative expression analysis of HLA-A,B and C genes on microdisected tumoral regions indicate higher HLA expression in regressing than in progressing metastases. The molecular signature obtained in melanoma rejection appeared to be similar to that observed in other forms of immune-mediated tissue-specific rejection such as allograft, pathogen clearance, graft versus host or autoimmune disease, supporting the immunological constant of rejection. We favor the idea that the major factor determining the success or failure of immunotherapy is the nature of HLA Class I alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will remain unchanged and the lesion will progress.

Original languageEnglish
Pages (from-to)387-395
Number of pages9
JournalInternational Journal of Cancer
Volume131
Issue number2
DOIs
Publication statusPublished - 15 Jul 2012
Externally publishedYes

Fingerprint

Antigen Presentation
Immunotherapy
Interferons
Melanoma
Neoplasm Metastasis
Genes
HLA-C Antigens
HLA-A Antigens
HLA-B Antigens
HLA-DR Antigens
Graft vs Host Disease
Autoimmune Diseases
Allografts
Up-Regulation
Genome
T-Lymphocytes
Gene Expression
Neoplasms

Keywords

  • HLA
  • immunotherapy
  • IRF-1
  • melanoma
  • metastasis
  • rejection

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. / Carretero, Rafael; Wang, Ena; Rodriguez, Ana I.; Reinboth, Jennifer; Ascierto, Maria L.; Engle, Alyson M.; Liu, Hui; Camacho, Francisco M.; Marincola, Francesco M.; Garrido, Federico; Cabrera, Teresa.

In: International Journal of Cancer, Vol. 131, No. 2, 15.07.2012, p. 387-395.

Research output: Contribution to journalArticle

Carretero, R, Wang, E, Rodriguez, AI, Reinboth, J, Ascierto, ML, Engle, AM, Liu, H, Camacho, FM, Marincola, FM, Garrido, F & Cabrera, T 2012, 'Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes', International Journal of Cancer, vol. 131, no. 2, pp. 387-395. https://doi.org/10.1002/ijc.26471
Carretero, Rafael ; Wang, Ena ; Rodriguez, Ana I. ; Reinboth, Jennifer ; Ascierto, Maria L. ; Engle, Alyson M. ; Liu, Hui ; Camacho, Francisco M. ; Marincola, Francesco M. ; Garrido, Federico ; Cabrera, Teresa. / Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. In: International Journal of Cancer. 2012 ; Vol. 131, No. 2. pp. 387-395.
@article{ce4119168ac5468c954a8e3f840d3f46,
title = "Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes",
abstract = "We present the results of a comparative gene expression analysis of 15 metastases (10 regressing and 5 progressing) obtained from 2 melanoma patients with mixed response following different forms of immunotherapy. Whole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients. In contrast, progressing metastases showed low transcription levels of genes involved in these pathways. Histological analysis showed T cells and HLA-DR positive infiltrating cells in the regressing but not in the progressing metastases. Quantitative expression analysis of HLA-A,B and C genes on microdisected tumoral regions indicate higher HLA expression in regressing than in progressing metastases. The molecular signature obtained in melanoma rejection appeared to be similar to that observed in other forms of immune-mediated tissue-specific rejection such as allograft, pathogen clearance, graft versus host or autoimmune disease, supporting the immunological constant of rejection. We favor the idea that the major factor determining the success or failure of immunotherapy is the nature of HLA Class I alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will remain unchanged and the lesion will progress.",
keywords = "HLA, immunotherapy, IRF-1, melanoma, metastasis, rejection",
author = "Rafael Carretero and Ena Wang and Rodriguez, {Ana I.} and Jennifer Reinboth and Ascierto, {Maria L.} and Engle, {Alyson M.} and Hui Liu and Camacho, {Francisco M.} and Marincola, {Francesco M.} and Federico Garrido and Teresa Cabrera",
year = "2012",
month = "7",
day = "15",
doi = "10.1002/ijc.26471",
language = "English",
volume = "131",
pages = "387--395",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

AU - Carretero, Rafael

AU - Wang, Ena

AU - Rodriguez, Ana I.

AU - Reinboth, Jennifer

AU - Ascierto, Maria L.

AU - Engle, Alyson M.

AU - Liu, Hui

AU - Camacho, Francisco M.

AU - Marincola, Francesco M.

AU - Garrido, Federico

AU - Cabrera, Teresa

PY - 2012/7/15

Y1 - 2012/7/15

N2 - We present the results of a comparative gene expression analysis of 15 metastases (10 regressing and 5 progressing) obtained from 2 melanoma patients with mixed response following different forms of immunotherapy. Whole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients. In contrast, progressing metastases showed low transcription levels of genes involved in these pathways. Histological analysis showed T cells and HLA-DR positive infiltrating cells in the regressing but not in the progressing metastases. Quantitative expression analysis of HLA-A,B and C genes on microdisected tumoral regions indicate higher HLA expression in regressing than in progressing metastases. The molecular signature obtained in melanoma rejection appeared to be similar to that observed in other forms of immune-mediated tissue-specific rejection such as allograft, pathogen clearance, graft versus host or autoimmune disease, supporting the immunological constant of rejection. We favor the idea that the major factor determining the success or failure of immunotherapy is the nature of HLA Class I alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will remain unchanged and the lesion will progress.

AB - We present the results of a comparative gene expression analysis of 15 metastases (10 regressing and 5 progressing) obtained from 2 melanoma patients with mixed response following different forms of immunotherapy. Whole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients. In contrast, progressing metastases showed low transcription levels of genes involved in these pathways. Histological analysis showed T cells and HLA-DR positive infiltrating cells in the regressing but not in the progressing metastases. Quantitative expression analysis of HLA-A,B and C genes on microdisected tumoral regions indicate higher HLA expression in regressing than in progressing metastases. The molecular signature obtained in melanoma rejection appeared to be similar to that observed in other forms of immune-mediated tissue-specific rejection such as allograft, pathogen clearance, graft versus host or autoimmune disease, supporting the immunological constant of rejection. We favor the idea that the major factor determining the success or failure of immunotherapy is the nature of HLA Class I alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will remain unchanged and the lesion will progress.

KW - HLA

KW - immunotherapy

KW - IRF-1

KW - melanoma

KW - metastasis

KW - rejection

UR - http://www.scopus.com/inward/record.url?scp=84861651644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861651644&partnerID=8YFLogxK

U2 - 10.1002/ijc.26471

DO - 10.1002/ijc.26471

M3 - Article

C2 - 21964766

AN - SCOPUS:84861651644

VL - 131

SP - 387

EP - 395

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -